AKOS BBS-00005529结构式
|
常用名 | AKOS BBS-00005529 | 英文名 | AKOS BBS-00005529 |
|---|---|---|---|---|
| CAS号 | 39033-45-9 | 分子量 | 202.03700 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C8H5Cl2NO | 熔点 | N/A | |
| MSDS | N/A | 闪点 | N/A |
| 英文名 | 3,3-Dichloro-1,3-dihydro-2H-indol-2-one |
|---|---|
| 英文别名 | 更多 |
| 分子式 | C8H5Cl2NO |
|---|---|
| 分子量 | 202.03700 |
| 精确质量 | 200.97500 |
| PSA | 29.10000 |
| LogP | 2.40710 |
| InChIKey | WGGLCBPNOIWKDL-UHFFFAOYSA-N |
| SMILES | O=C1Nc2ccccc2C1(Cl)Cl |
| 海关编码 | 2933990090 |
|---|
|
~49%
AKOS BBS-00005529 39033-45-9 |
| 文献:Dolci, Sara; Marchetti, Fabio; Pampaloni, Guido; Zacchini, Stefano Dalton Transactions, 2013 , vol. 42, # 16 p. 5635 - 5648 |
|
~%
AKOS BBS-00005529 39033-45-9 |
| 文献:Kanamori, Kan; Kataoka, Hiroshi; Matsugo, Seiichi European Journal of Inorganic Chemistry, 2012 , # 29 p. 4570 - 4573 |
| AKOS BBS-00005529上游产品 2 | |
|---|---|
| AKOS BBS-00005529下游产品 5 | |
| 海关编码 | 2933990090 |
|---|---|
| 中文概述 | 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
| 申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
实验名称:NCI human tumor cell line growth inhibition assay. Data for the MCF7 Non-Small Cell L...
来源:DTP/NCI
靶标:N/A
External Id:MCF7_OneDose
|
|
实验名称:NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Non-Small Cell...
来源:DTP/NCI
靶标:N/A
External Id:IGROV1_OneDose
|
| 3,3'-Dichlor-2,2'-piperazin-1,4-diyl-di-[1,4]naphthochinon |
| 2,2'-Piperazine-1,4-diylbis(3-chloronaphthoquinone) |
| 3,3-Dichlor-indolin-2-on |
| 3,3'-dichloro-2,2'-piperazine-1,4-diyl-di-[1,4]naphthoquinone |
| 3,3-Dichlor-oxindol |
| 3,3-dichloro-indolin-2-one |
| 1,4-bis(3-chloro-1,4-naphthoquinon-2-yl)piperazin |
| 3,3-Dichloro-2,3-dihydroindol-2-one |
| 3,3-dichloro-2-oxoindole |
| 3,3-dichloro-2,3-dihydro-1H-indol-2-one |
| 1,4-Bis-(2-chlor-1,4-naphthochinonyl-(3))-piperazin |
| 3,3-dichloro-oxindole |